Skip to main content
. 2022 May 26;18(3):e081221198647. doi: 10.2174/1573403X17666211208100151

Table 1.

Design of studies and characteristics of participants.

First Author [Ref. #] Type of Study, Country, Year Criteria for Inclusion of Participants Number of Patients Male Gender Age (Years) Ejection Fraction (%) Indications Underlying Heart Disease
Primary Prevention Secondary Prevention CM
(Ischemic, Non Ischemic, Dilated)
CAD/ IHD HCM Others
ICD-S ICD-TV ICD-S (%) ICD-TV (%) ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV ICD-S ICD-TV
Köbe et al. [13] Case-control, Germany, 2013 Primary and secondary prevention 69 69 50 (72) 50
(72)
45.7 47.7 46.2 40.6 41
(59)
34
(49)
28
(41)
35
(51)
25
(36)
32
(46)
11
(16)
13
(19)
10
(14)
4
(6)
24
(35)
22
(32)
Pedersen et al. [14] Case-control, Czech Republic, Denmark, Germany, Italy, Netherlands, New Zealand, Portugal, United Kingdom, 2016 Primary and secondary prevention 167 167 122 (73) 120
(72)
54 55 NR NR 123
(74)
115
(69)
44 (26) 52 (31) 37
(22)
51
(30)
- - 22
(13)
18
(11)
76
(45)
82
(49)
Brouwer et al. [12] Case-control, Netherlands, 2016 Primary and secondary prevention 140 140 84 (60) 87
(62)
41 42 50 49 93
(66)
86
(61)
47 (34) 54 (39) 54
(39)
71
(51)
- - - - 84
(61)
68
(49)
Botto et al. [11] Cohort, Italy, 2017 Primary and secondary prevention 62 448 45
(73)
354
(79)
47 67 49 34 30 (48) 357 (80) 32
(52)
91
(20)
21
(34)
362
(81)
18
(29)
275
(61)
9
(14)
16
(4)
9
(14)
47
(10)
Knops et al. [15,24] Non-inferiority trial, Germany, Netherlands, United Kingdom, United States, 2020 Primary and secondary prevention 426 423 337 (79.1) 345 (81.6) 63 64 30 30 346 (81.2) 339 (80.1) 80 (18.8) 84 (19.9) 388 (91) 396 (93.6) NR NR 15 (3.5) 7 (1.7) 38 (8.9) 27 (6.38)

CM= cardiomyopathy; CAD= coronary artery disease; IHD= ischemic Heart Disease; HCM= hypertrophic cardiomyopathy; ICD-S= subcutaneous implantable cardioverter defibrillator; ICD-TV= transvenous implantable cardioverter defibrillator.